FDA Laboratories: Magnitude of Benefits Associated With Consolidation Is Questionable
HEHS-96-30
Published: Mar 19, 1996. Publicly Released: Mar 19, 1996.
Skip to Highlights
Highlights
Pursuant to a congressional request, GAO reviewed the Food and Drug Administration's (FDA) plan to consolidate its Office of Regulatory Affairs' (ORA) 18 field laboratories for product testing, focusing on: (1) the validity of projected cost savings and operational efficiencies; and (2) site selection criteria.
Recommendations
Recommendations for Executive Action
| Agency Affected | Recommendation | Status |
|---|---|---|
| Food and Drug Administration | The Commissioner, FDA, should review the restructuring plan to determine whether ORA adequately weighed the benefits of consolidation relative to other alternatives. |
Closed – Implemented
FDA reevaluated its restructuring plan and concluded that it should continue implementing the plan.
|
Full Report
Office of Public Affairs
Topics
Cost effectiveness analysisFederal agency reorganizationFederal facility relocationFood and drug lawLaboratoriesObsolete facilitiesProduct safetySite selectionTest facilitiesConstruction